CA2438960A1 - Influenza vaccine formulations for intradermal delivery - Google Patents

Influenza vaccine formulations for intradermal delivery Download PDF

Info

Publication number
CA2438960A1
CA2438960A1 CA002438960A CA2438960A CA2438960A1 CA 2438960 A1 CA2438960 A1 CA 2438960A1 CA 002438960 A CA002438960 A CA 002438960A CA 2438960 A CA2438960 A CA 2438960A CA 2438960 A1 CA2438960 A1 CA 2438960A1
Authority
CA
Canada
Prior art keywords
vaccine
virus
use according
influenza
intradermal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002438960A
Other languages
English (en)
French (fr)
Inventor
Nathalie Garcon
Moncef Mohamed Slaoui
Christian Van Hoecke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0104542A external-priority patent/GB0104542D0/en
Priority claimed from GB0108366A external-priority patent/GB0108366D0/en
Application filed by Individual filed Critical Individual
Publication of CA2438960A1 publication Critical patent/CA2438960A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16163—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002438960A 2001-02-23 2002-02-21 Influenza vaccine formulations for intradermal delivery Abandoned CA2438960A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0104542.6 2001-02-23
GB0104542A GB0104542D0 (en) 2001-02-23 2001-02-23 Novel vaccine
GB0108366.6 2001-04-03
GB0108366A GB0108366D0 (en) 2001-04-03 2001-04-03 Novel compounds
PCT/EP2002/001843 WO2002067983A1 (en) 2001-02-23 2002-02-21 Novel vaccine

Publications (1)

Publication Number Publication Date
CA2438960A1 true CA2438960A1 (en) 2002-09-06

Family

ID=26245752

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002438960A Abandoned CA2438960A1 (en) 2001-02-23 2002-02-21 Influenza vaccine formulations for intradermal delivery

Country Status (6)

Country Link
US (2) US20040096463A1 (cg-RX-API-DMAC7.html)
EP (1) EP1361889A1 (cg-RX-API-DMAC7.html)
JP (1) JP2004536785A (cg-RX-API-DMAC7.html)
AR (1) AR032575A1 (cg-RX-API-DMAC7.html)
CA (1) CA2438960A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002067983A1 (cg-RX-API-DMAC7.html)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL355287A1 (en) * 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Intranasal influenza virus vaccine
EP1361890B1 (en) * 2001-02-23 2011-03-30 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
CA2445120A1 (en) * 2001-04-27 2002-11-07 Glaxosmithkline Biologicals Sa Devices for the intradermal administration of influenza vaccines
MY134424A (en) * 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
CN1253220C (zh) * 2001-06-29 2006-04-26 贝克顿迪肯森公司 通过微管在真皮内输入疫苗和基因治疗剂
US7588774B2 (en) 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
AU2004249802B2 (en) 2003-06-20 2007-06-28 Microbix Biosystems Inc. Improvements in virus production
US20080254065A1 (en) 2004-03-09 2008-10-16 Chiron Corporation Influenza Virus Vaccines
CN101124343A (zh) 2004-04-01 2008-02-13 阿尔扎公司 用于经皮肤输送流感疫苗的装置和方法
WO2005113756A1 (en) * 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
AU2005314563B2 (en) * 2004-11-03 2011-06-30 Seqirus UK Limited Influenza vaccination
WO2006060710A2 (en) * 2004-12-02 2006-06-08 Becton, Dickinson And Company Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
ATE494906T1 (de) 2005-11-01 2011-01-15 Novartis Vaccines & Diagnostic Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna
WO2007052055A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
ES2377884T3 (es) 2005-11-04 2012-04-02 Novartis Vaccines And Diagnostics S.R.L. Vacunas contra la gripe que incluyen combinaciones de adyuvantes particulados e inmunopotenciadores
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
CA2628424A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted influenza vaccines including cytokine-inducing agents
KR20080069232A (ko) 2005-11-04 2008-07-25 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. 스플리트 인플루엔자 백신에 대한 보조제로서 유리 수성상계면활성제를 갖는 에멀젼
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
PL2478916T3 (pl) 2006-01-27 2020-11-16 Seqirus UK Limited Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
WO2007110776A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
NZ575271A (en) 2006-09-11 2011-09-30 Novartis Ag Making influenza virus vaccines without using eggs
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
JP2011506264A (ja) 2006-12-06 2011-03-03 ノバルティス アーゲー インフルエンザウイルスの４つの株に由来する抗原を含むワクチン
PT2185191E (pt) 2007-06-27 2012-11-27 Novartis Ag Vacinas contra a gripe com baixo teor de aditivos
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP2235532B1 (en) 2007-12-24 2013-04-24 Novartis AG Assays for adsorbed influenza vaccines
US8506966B2 (en) * 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
JP5518041B2 (ja) 2008-03-18 2014-06-11 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良
RU2011107757A (ru) 2008-08-01 2012-09-10 Гамма Ваксинс Пти Лимитед (Au) Вакцины против гриппа
EP2361304A2 (en) 2008-11-05 2011-08-31 GlaxoSmithKline Biologicals S.A. Novel method
WO2010089339A1 (en) * 2009-02-06 2010-08-12 Glaxosmithkline Biologicals S.A. Purification of virus or viral antigens by density gradient ultracentrifugation
EA023662B1 (ru) 2009-02-10 2016-06-30 Новартис Аг Вакцины против гриппа со сниженным количеством сквалена
JP2012517416A (ja) 2009-02-10 2012-08-02 ノバルティス アーゲー 増加した量のｈ３抗原を含むインフルエンザワクチン
WO2010092476A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
DE102010018462A1 (de) 2009-04-27 2011-04-07 Novartis Ag Impfstoffe zum Schutz gegen Influenza
JP5836266B2 (ja) 2009-05-21 2015-12-24 ノバルティス アーゲー 非内因性ｐｏｌＩプロモーターを使用した逆遺伝学
WO2011012999A1 (en) 2009-07-31 2011-02-03 Novartis Ag Reverse genetics systems
CN102695523A (zh) 2009-09-10 2012-09-26 诺华有限公司 针对呼吸道疾病的组合疫苗
KR20120083480A (ko) 2009-10-20 2012-07-25 노파르티스 아게 바이러스 구제를 위한 개선된 역유전학 방법
JP6072677B2 (ja) 2010-05-06 2017-02-01 ノバルティス アーゲー 微生物の不活化のための有機ペルオキシド化合物
JP5876036B2 (ja) 2010-05-21 2016-03-02 ノバルティス アーゲー インフルエンザウイルス再集合方法
PL2575872T3 (pl) 2010-06-01 2021-02-22 Seqirus UK Limited Zatężanie antygenów szczepionkowych grypy bez liofilizacji
CA2801151A1 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens with lyophilization
WO2011154976A2 (en) 2010-06-08 2011-12-15 Panacea Biotec Limited Improved influenza vaccine
CA2808965C (en) 2010-08-20 2020-01-07 Theraject, Inc. Soluble needle arrays for delivery of influenza vaccines
WO2012100302A1 (en) 2011-01-27 2012-08-02 Gamma Vaccines Pty Limited Combination vaccines
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
EP2768528A1 (en) 2011-10-20 2014-08-27 Novartis AG Adjuvanted influenza b virus vaccines for pediatric priming
WO2013087945A2 (en) 2012-03-02 2013-06-20 Novartis Ag Influenza virus reassortment
CN104159608A (zh) 2012-03-06 2014-11-19 克鲁塞尔荷兰公司 针对流感的改善的疫苗接种
WO2013182498A1 (en) 2012-06-04 2013-12-12 Novartis Ag Improved safety testing
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
US9708585B2 (en) 2012-12-03 2017-07-18 Seqirus UK Limited Influenza virus reassortment
AU2014204826A1 (en) 2013-01-10 2015-07-09 Seqirus UK Limited Influenza virus immunogenic compositions and uses thereof
CA2905612A1 (en) 2013-03-13 2014-09-18 Novartis Ag Influenza virus reassortment
JP2016521282A (ja) 2013-05-10 2016-07-21 ノバルティス アーゲー インフルエンザワクチンにおけるナルコレプシーのリスクの回避
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
CN105722976A (zh) 2013-06-06 2016-06-29 诺华股份有限公司 流感病毒重配
CA2930634C (en) 2013-11-15 2023-05-09 Novartis Ag Removal of influenza nuclear protein (np) from influenza virus preparations
FR3025107B1 (fr) 2014-08-29 2018-10-05 Calixar Procede de preparation d'un antigene vaccinal, antigene vaccinal obtenu et utilisations
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
KR20180035807A (ko) 2015-06-26 2018-04-06 세퀴러스 유케이 리미티드 항원적으로 매치된 인플루엔자 백신
AU2016290603B2 (en) 2015-07-07 2022-06-02 Seqirus UK Limited Influenza potency assays
US10626376B2 (en) 2016-11-14 2020-04-21 St. Jude Children's Research Hospital Method for isolating and purifying adeno-associated virus particles using salt
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
US20220168413A1 (en) 2019-02-25 2022-06-02 Seqirus UK Limited Adjuvanted multivalent influenza vaccines
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
EP4054630A2 (en) 2019-11-07 2022-09-14 Seqirus UK Limited Compositions and methods for producing a viral vaccine with reduced particle size
EP4061930A1 (en) 2019-11-18 2022-09-28 Seqirus Pty Ltd Method for producing reassortant influenza viruses
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
IT202100014747A1 (it) * 2021-06-07 2022-12-07 Consiglio Nazionale Ricerche Derivati sterolici come nuovi ligandi del recettore dectina-1 nel trattamento terapeutico di patologie correlate a tale recettore

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1274081A (en) * 1917-05-10 1918-07-30 Herman A Metz Hypodermic needle.
US1436707A (en) * 1921-08-10 1922-11-28 American Platinum Works Adjustable and safety regulating device for hypodermic needles
FR1001668A (fr) * 1946-06-17 1952-02-26 Seringue pour anesthésie tronculaire du maxillaire inférieur
US2559474A (en) * 1950-03-09 1951-07-03 Sonco Inc Hypodermic and spinal syringe
FR1072399A (fr) * 1961-01-07 1954-09-13 Injecteur intra-dermique
US3400715A (en) * 1966-01-04 1968-09-10 Halvard J. Pederson Attachment for injection apparatus
US3964482A (en) * 1971-05-17 1976-06-22 Alza Corporation Drug delivery device
BE795384A (fr) * 1972-02-14 1973-08-13 Ici Ltd Pansements
JPS6153226A (ja) * 1984-08-24 1986-03-17 Chemo Sero Therapeut Res Inst 単純ヘルペスサブユニツトワクチンの精製方法
CA1283827C (en) * 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
US6056716A (en) * 1987-06-08 2000-05-02 D'antonio Consultants International Inc. Hypodermic fluid dispenser
US5569190A (en) * 1987-06-08 1996-10-29 D'antonio; Nicholas F. Hypodermic fluid dispenser
US5080648A (en) * 1987-06-08 1992-01-14 Antonio Nicholas F D Hypodermic fluid dispenser
US5195526A (en) * 1988-03-11 1993-03-23 Michelson Gary K Spinal marker needle
TW279133B (cg-RX-API-DMAC7.html) * 1990-12-13 1996-06-21 Elan Med Tech
SE9102652D0 (sv) * 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) * 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
IL101720A (en) * 1992-04-29 1998-09-24 Mali Tech Ltd Needle for syringe or the like
US5686078A (en) * 1992-09-14 1997-11-11 Connaught Laboratories, Inc. Primary and secondary immunization with different physio-chemical forms of antigen
CN1124013A (zh) * 1993-02-19 1996-06-05 史密丝克莱恩比彻姆公司 含3-邻位-脱酰基的单磷酰基脂质a的流感疫苗组合物
CA2156525A1 (en) * 1993-02-19 1994-09-01 Susan Dillon Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
US6485729B1 (en) * 1993-09-13 2002-11-26 Protein Sciences Corporation Neuraminidase-supplemented compositions
US5997501A (en) * 1993-11-18 1999-12-07 Elan Corporation, Plc Intradermal drug delivery device
GB9620795D0 (en) * 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
SE9502285D0 (sv) * 1995-06-22 1995-06-22 Pharmacia Ab Improvements related to injections
US5776107A (en) * 1996-12-31 1998-07-07 Delab Injection device
IT1298087B1 (it) * 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6494865B1 (en) * 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
US6776776B2 (en) * 1999-10-14 2004-08-17 Becton, Dickinson And Company Prefillable intradermal delivery device
US6843781B2 (en) * 1999-10-14 2005-01-18 Becton, Dickinson And Company Intradermal needle
US6569143B2 (en) * 1999-10-14 2003-05-27 Becton, Dickinson And Company Method of intradermally injecting substances
US20020193740A1 (en) * 1999-10-14 2002-12-19 Alchas Paul G. Method of intradermally injecting substances
US6569123B2 (en) * 1999-10-14 2003-05-27 Becton, Dickinson And Company Prefillable intradermal injector
EP1361890B1 (en) * 2001-02-23 2011-03-30 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
GB0109297D0 (en) * 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
CA2445120A1 (en) * 2001-04-27 2002-11-07 Glaxosmithkline Biologicals Sa Devices for the intradermal administration of influenza vaccines
CN1253220C (zh) * 2001-06-29 2006-04-26 贝克顿迪肯森公司 通过微管在真皮内输入疫苗和基因治疗剂

Also Published As

Publication number Publication date
WO2002067983A1 (en) 2002-09-06
US20040096463A1 (en) 2004-05-20
AR032575A1 (es) 2003-11-12
EP1361889A1 (en) 2003-11-19
JP2004536785A (ja) 2004-12-09
US20140302090A1 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
US9138471B2 (en) Methods for one-dose intradermal delivery for non-live trivalent influenza vaccine
US20140302090A1 (en) Novel vaccine
CA2383105C (en) Intranasal influenza virus vaccine
CA2448208C (en) Influenza vaccine composition
AU2002344182A1 (en) Influenza vaccine composition
CA2445120A1 (en) Devices for the intradermal administration of influenza vaccines
ES2361981T3 (es) Formulaciones de vacunas de la gripe para administración intradérmica.
HK1147213A (en) Influenza vaccine formulations for intradermal delivery
HK1145984A (en) Influenza vaccine formulations for intradermal delivery

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20160519